Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.

Authors:
  • EVE Vaskaridou
    E Vaskaridou
  • KKK Konstantopoulos
    K Konstantopoulos
  • DKD Kyriakou
    D Kyriakou
  • DLD Loukopoulos
    D Loukopoulos

  • 1 May 1993
    • journal article
    • case report
    • Vol. 78  (3) , 183-4
    • PMID:8375749
Abstract
We report two cases of transfusion-dependent thalassemia treated by deferoxamine during the first trimesters of two successful pregnancies. The absence of any sign(s) of toxicity or teratogenicity is remarkable; despite the data from animal models, it seems that deferoxamine in humans is rather harmless for the fetus at the usually recommended doses.